{
    "nctId": "NCT04680442",
    "briefTitle": "Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction",
    "officialTitle": "Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction: A Randomized, Controlled Trial",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Heart Failure",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 130,
    "primaryOutcomeMeasure": "primary efficacy outcome",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Stage I-III HER-2 positive breast cancer\n2. Receiving adjuvant or neoadjuvant therapy with trastuzumab, pertuzumab, or trastuzumab-emtansine (T-DM1)\n3. Evidence of left ventricular dysfunction, as defined by at least one of:\n\n   a) LVEF \\< 54% or b) LVEF \u226554% and either i) fall in LVEF of \u226515% from prior to trastuzumab, pertuzumab, or trastuzumab-emtansine (T-DM1) exposure, or ii) New York Heart Association (NYHA) class II heart failure symptoms within the past 6 months\n\nExclusion Criteria:\n\n1. Current use of both angiotensin converting enzyme inhibitor (ACEI) /angiotensin receptor blocker (ARB) and beta-blocker\n2. Contra-indication to both ACE-I/ARB and beta-blockers\n3. NYHA class III or IV heart failure\n4. LVEF \\<40%\n5. Systolic blood pressure \\<100mmHg\n6. Current or planned pregnancy or breastfeeding",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}